Literature DB >> 33369357

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

Harold J Burstein1.   

Abstract

Entities:  

Year:  2020        PMID： 33369357     DOI： 10.1056/NEJMra1307118

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  34 in total

1.  Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years.

Authors:  Lisi M Dredze; Michael Friger; Samuel Ariad; Michael Koretz; Bertha Delgado; Ruthy Shaco-Levy; Margarita Tokar; Michael Bayme; Ravit Agassi; Maia Rosenthal; Victor Dyomin; Olga Belochitski; Shai Libson; Tamar Mizrahi; David B Geffen
Journal:  Breast Cancer Res Treat       Date:  2022-04-22       Impact factor: 4.872

2.  Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor.

Authors:  Jia Gu; Neng Zhu; Hong-Fang Li; Tan-Jun Zhao; Chan-Juan Zhang; Duan-Fang Liao; Li Qin
Journal:  Cell Oncol (Dordr)       Date:  2022-07-22       Impact factor: 7.051

3.  Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysis.

Authors:  Dalang Fang; Yanting Li; Yanghong Li; Yongcheng Chen; Qianfang Huang; Zhizhai Luo; Jinghua Chen; Yingjin Li; Zaizhi Wu; Yuanlu Huang; Yanfei Ma
Journal:  Gland Surg       Date:  2022-06

4.  Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen receptor-positive breast cancer via the HIF-1α-dependent pathway.

Authors:  Qing Robert Miao; Ying Jin; Zhimin Fan; Chang Liu; Sijie Li; Xiaoxiao Zhang; Chunxiang Jin; Baofeng Zhao; Liying Li
Journal:  Cancer Gene Ther       Date:  2022-10-14       Impact factor: 5.854

Review 5.  Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer.

Authors:  Alexander Ring; Maria Spataro; Andreas Wicki; Nicola Aceto
Journal:  Front Cell Dev Biol       Date:  2022-06-28

Review 6.  Metastasis prevention: targeting causes and roots.

Authors:  A A Schegoleva; A A Khozyainova; T S Gerashchenko; L D Zhuikova; Evgeny V Denisov
Journal:  Clin Exp Metastasis       Date:  2022-03-26       Impact factor: 4.510

7.  Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer.

Authors:  Sibylle Loibl; Jenny Furlanetto
Journal:  Breast       Date:  2021-12-13       Impact factor: 4.254

Review 8.  Epigenetic mechanisms in breast cancer therapy and resistance.

Authors:  Liliana Garcia-Martinez; Yusheng Zhang; Yuichiro Nakata; Ho Lam Chan; Lluis Morey
Journal:  Nat Commun       Date:  2021-03-19       Impact factor: 14.919

9.  Importance of Patient Education for At-home Yoga Practice in Women With Hormonal Therapy-induced Pain During Adjuvant Breast Cancer Treatment: A Feasibility Study.

Authors:  Kerstin Faravel; Marie-Eve Huteau; Marta Jarlier; Hélène de Forges; Laetitia Meignant; Pierre Senesse; Joanna Norton; William Jacot; Anne Stoebner
Journal:  Integr Cancer Ther       Date:  2021 Jan-Dec       Impact factor: 3.279

Review 10.  Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?

Authors:  Benoîte Mery; Coralie Poulard; Muriel Le Romancer; Olivier Trédan
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.